Abstract:Background Apical membrane antigen 1 (AMA-1) and merozoite surface protein 1 (MSP1) of Plasmodium falciparum are two leading blood-stage malaria vaccine candidates. A P. falciparum chimeric protein 2.9 (PfCP-2.9) has been constructed as a vaccine candidate, by fusing AMA-1 domain III (AMA-1 (III)) with a C-terminal 19 kDa fragment of MSP1 (MSP1-19) via a 28-mer peptide hinge. PfCP-2.9 was highly immunogenic in animal studies, and antibodies elicited by the PfCP-2.9 highly inhibited parasite growth in vitro . This study focused on locating the distribution of epitopes on PfCP-2.9. Methods A panel of anti-PfCP-2.9 monoclonal antibodies (mAbs) were produced and their properties were examined by Western blot as well as in vitro growth inhibition assay (GIA). In addition, a series of PfCP-2.9 mutants containing single amino acid substitution were produced in Pichia pastoris . Interaction of the mAbs with the PfCP-2.9 mutants was measured by both Western blot and enzyme-linked immunosorbent assay (ELISA). Results Twelve mAbs recognizing PfCP-2.9 chimeric protein were produced. Of them, eight mAbs recognized conformational epitopes and six mAbs showed various levels of inhibitory activities on parasite growth in vitro . In addition, seventeen PfCP-2.9 mutants with single amino acid substitution were produced in Pichia pastoris for interaction with mAbs. Reduced binding of an inhibitory mAb (mAb7G), was observed in three mutants including M62 (Phe 491 →Ala), M82 (Glu 511 →Gln) and M84 (Arg 513 →Lys), suggesting that these amino acid substitutions are critical to the epitope corresponding to mAb7G. The binding of two non-inhibitory mAbs (mAbG11.12 and mAbW9.10) was also reduced in the mutants of either M62 or M82. The substitution of Leu 31 to Arg resulted in completely abolishing the binding of mAb1E1 (a blocking antibody) to M176 mutant, suggesting that the Leu residue at this position plays a crucial role in the formation of the epitope. In addition, the Asn 15 residue may also play an important role in the global folding of PfCP-2.9, as its substitution by Arg lead to reduced binding of most mAbs and abolishing the binding of mAb6G and mAbP5-W12. Conclusions This study provided valuable information on epitopes of PfCP-2.9 vaccine candidate through generation of a panel of mAbs and a series of PfCP-2.9 mutants. The information may prove to be useful for designing more effective malaria vaccines against blood-stage parasites.

Immunogenieity Analysis of 42 Kda C-terminal Region of Merozoite Surface Protein 1 of Plasmodiun Falciparum Expressed in Rosetta Gami

Synthesis and Expression of 42 Kda C-terminal Region of the Major Merozoite Surface Protein1 (MSP1-42) of Plasmodium Falciparum in Rosetta Gami

Specific antibodies against recombinant MSP1 of Plasmodium falciparum strongly inhibit the parasite growth in vitro

The Production and Immunogenicity of the Functional Fragment of Plasmodium Falciparum Merozoite Surface Protein 3

Analysis of recombinant merozoite surface protein-1 of Plasmodium falciparum expressed in mammalian cells

[Synthesis and Expression of 42 Kd C-terminal Region of the Major Merozoite Surface Protein (MSP1 - 42) of P. Falciparum 3D7 Strain in Pichia Pastoris].

Comparison of Immunogenicity of Five MSP1-based Malaria Vaccine Candidate Antigens in Rabbits

Blood-Stage Vaccine Candidate of Plasmodium Falciparum

Expression and the Immune Response of the EGF2 Domain in the Merozoite Surface Protein 1 of Plasmodium Faciparum

Rice‐produced MSP142 of Plasmodium Falciparum Elicits Antibodies That Inhibit Parasite Growth in Vitro

Epitope Mapping of PfCP-2.9, an Asexual Blood-Stage Vaccine Candidate of Plasmodium Falciparum

Construction of a Vaccinia Virus Vectored Multi-Epitope Vaccine Candidate for Plasmodium Falciparum

Systematic Analysis of Natural Antibody Responses to P. Falciparum Merozoite Antigens by Protein Arrays.

Construction of Transgenic Plasmodium Berghei As a Model for Evaluation of Blood-Stage Vaccine Candidate of Plasmodium Falciparum Chimeric Protein 2.9.

Immunogenicity Analysis of the Recombinant Plasmodium falciparum Surface-Related Antigen in Mice

Production of High-Affinity Human Monoclonal Antibody Fab Fragments to the 19-Kilodalton C-Terminal Merozoite Surface Protein 1 Ofplasmodium Falciparum

[Construction and Expression of Plasmodium Berghei Chimeric Protein in Pichia Pastoris and Its Immunogenicity in Mice].

Full-length MSP1 is a major target of protective immunity after controlled human malaria infection

Expression and immunogenicity analysis of membrane surface protein 2 of Anaplasma marginale

Natural Plasmodium falciparum Infection Stimulates Human Antibodies to MSP1 Epitopes Identified in Mice Infection Models upon Non-Natural Modified Peptidomimetic Vaccination

Solution structure of a Plasmodium falciparum AMA-1/MSP 1 chimeric protein vaccine candidate (PfCP-2.9) for malaria